Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 44Specimen Handling 38enzalutamide 30Nivolumab 30pembrolizumab 28Docetaxel 23Gemcitabine 22apalutamide 20Prednisone 20Biopsy 20Abiraterone Acetate 18Androgen Antagonists 17cabozantinib 14darolutamide 13abiraterone 13Radiotherapy 13Cisplatin 12enfortumab vedotin 11Radiation 11Ipilimumab 11Pluvicto 10erdafitinib 9belzutifan 9atezolizumab 9X-Rays 9Radiosurgery 9Mitomycin 9olaparib 8cabazitaxel 8Standard of Care 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
hydroxycamptothecinum × Genitourinary × 30 days × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡